Published in Lab Business Week, September 4th, 2005
For the first fiscal quarter ended June 30, 2005, Abaxis reported revenues of $14.3 million, as compared with revenues of $13.2 million for the comparable period last year, an increase of 8%. Instrument revenue and recurring reagent disc and hematology reagent revenue increased by $775,000 or 6% over the same period last year. The company reported net income attributable to common shareholders of $1.0 million, compared to $1.4 million for the same period last year.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.